MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
42.63
+0.20
+0.47%
After Hours: 42.63 0 0.00% 16:10 02/10 EST
OPEN
43.00
PREV CLOSE
42.43
HIGH
43.67
LOW
42.13
VOLUME
881.59K
TURNOVER
--
52 WEEK HIGH
46.60
52 WEEK LOW
26.74
MARKET CAP
3.29B
P/E (TTM)
-10.9741
1D
5D
1M
3M
1Y
5Y
1D
Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel
TipRanks · 10h ago
XENON PHARMACEUTICALS INC <XENE.O>: STIFEL RAISES TARGET PRICE TO $66 FROM $60
Reuters · 10h ago
Weekly Report: what happened at XENE last week (0202-0206)?
Weekly Report · 1d ago
Analysts Conflicted on These Healthcare Names: CVS Health (CVS), Madrigal Pharmaceuticals (MDGL) and Xenon (XENE)
TipRanks · 02/03 12:10
Weekly Report: what happened at XENE last week (0126-0130)?
Weekly Report · 02/02 09:25
Weekly Report: what happened at XENE last week (0119-0123)?
Weekly Report · 01/26 09:25
Xenon (XENE) Receives a Buy from J.P. Morgan
TipRanks · 01/20 12:36
Weekly Report: what happened at XENE last week (0112-0116)?
Weekly Report · 01/19 09:28
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.